Heart Diseases Cies Search Engine [selected websites]

Loading

Thursday, July 5, 2012

MicroMed Cardiovascular's HeartAssist 5™ Goes Wireless

MicroMed Cardiovascular
June 21, 2012 - Breakthrough Technology Advances Remote Monitoring Capabilities of the HeartAssist 5® System to Wirelessly Report Data when Patients are on the MoveMicroMed Cardiovascular Inc., manufacturer of the HeartAssist 5™ Left Ventricular Assist Device (LVAD), recently integrated the capacity for continuous wireless monitoring into its Conquest Controller. The Conquest Controller release is pending approval by regulatory agencies.

This unprecedented innovation will allow continual remote monitoring of data from the Heart Assist 5 LVAD. As a result, clinicians, doctors and technicians will be informed automatically and in the background without requiring the patient to do anything or having to come in to the clinic or hospital facilities.

Prior to MicroMed’s implementation of the M2M technology, clinicians could only access device data when the patient physically plugged the HeartAssist 5 into MicroMed’s HeartAttendant™ so that data could be transmitted via a local internet connection. The internet solution provided useful data, but limited patient mobility, and meant data reporting could not be continuous... MicroMed Cardiovascular's Press Release -

Friday, May 18, 2012

Loma Vista Medical : CE mark for its TRUE Dilatation™ Balloon Valvuloplasty Catheter

Loma Vista Medical
May 10, 2012 - Loma Vista Medical (“LVM”) announced that it has received CE mark for its TRUE Dilatation™ Balloon Valvuloplasty Catheter. The company has seen rapid adoption at major clinical centers and will be launching its initial product at next week’s EuroPCR congress in Paris (Booth #M22, Paris Convention Center Palais des Congrès).

Fabricated from tough, high-strength materials and designed to prevent the catastrophic failures seen with other heart valve dilatation balloons, the TRUE Dilatation Balloon is highly resistant to ruptures, punctures, and tears. Studies funded by the U.S. National Heart, Lung and Blood Institute (NHBLI) and others have reported a 10% to 17% failure rate in conventional balloons used in BAV (balloon aortic valvuloplasty) and TAVI (transcatheter aortic valve implantation) procedures... [PDF] Loma Vista Medical's Press Release -

Friday, April 20, 2012

Quantum Genomics : initiation of a First-in-Human clinical study with QGC001, its lead compound for the treatment of hypertension

Quantum Genomics
April 13th 2012 - Quantum Genomics (NYSE Euronext Paris : MLQGC), following the approval from the French Agency for Safety of Health Products (AFSSAPS), announces the initiation of a phase I clinical study in healthy volunteers with its product QGC001. QGC001 is the first of a new class of drugs that is able to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.

Arterial hypertension affects an estimated 1 billion people worldwide (13 million people in France). Despite the availability of many antihypertensive drugs, 30% to 60% of patients diagnosed with hypertension do not have their blood pressure properly controlled by current medications for various reasons (49% in France ([1])). Moreover, the overall incidence of resistant hypertension to at least three antihypertensive drugs (including a diuretic) is estimatedaround 8% to 12% of the hypertensive population... Quantum Genomics' Press Release -

Tuesday, April 3, 2012

HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million

HeartWare International
March 29, 2012 - HeartWare International, Inc. (Nasdaq:HTWR) (ASX:HIN), which develops and manufactures miniaturized ventricular assist devices, and World Heart Corporation (Nasdaq:WHRT), which has been engaged in the development of left ventricular assist devices, announced that they have entered into a definitive merger agreement under which HeartWare will acquire WorldHeart for consideration of US$8 million, which will be paid in shares of HeartWare common stock or cash, at HeartWare's election.

WorldHeart Corporation

"WorldHeart has been an important participant in the development of ventricular assist therapies for many years and has amassed over one hundred patents and patent applications. In line with our goal to be a leader in the VAD market for years to come, we believe that bolstering our patent portfolio and adding WorldHeart's technologies broadens our options for the future," said Doug Godshall, President and CEO of HeartWare. "While we are intensely focused on the FDA panel for our HVAD® System next month, and commencement of first-in-man studies for our MVAD® System mid-year, we look forward to integrating WorldHeart's technologies and members of its talented team into our research efforts."... HeartWare International's Press ReleaseWorldHeart Corporation's Press Release  -

Tuesday, March 20, 2012

Asahi Kasei : Agreement to Acquire ZOLL Medical

Asahi Kasei
March 12, 2012 - Builds on existing relationship to drive global development of critical care businesses

Asahi Kasei Corporation (TSE1: 3407, hereinafter: Asahi Kasei), and ZOLL Medical Corporation (NASDAQ GS: ZOLL, hereinafter: ZOLL) jointly announced that Asahi Kasei, Japan’s leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion. The transaction has been approved by the Boards of Directors of both companies.

ZOLL Medical

Asahi Kasei, through a U.S. subsidiary, will make a cash tender offer to purchase all of the outstanding shares of ZOLL common stock for $93 per share. The purchase price represents a premium of 29.6% over ZOLL’s volume weighted average closing stock price over the 30 trading day period ended March 9, 2012, and a 23.8% premium over the closing price on March 9, 2012. The tender offer is expected to commence within 10 business days and will remain open for a minimum of 20 business days. Closing of the tender offer is subject to customary conditions, including receipt of applicable regulatory clearances and the minimum tender of at least two-thirds of the outstanding shares of ZOLL (on a fully diluted basis). The transaction is not subject to a financing condition. The ZOLL Board of Directors has recommended that ZOLL stockholders accept the offer and tender their shares into the offer when it is made. The transaction is expected to close in the second calendar quarter of 2012... Asahi Kasei's Press Release - ZOLL Medical's Press Release -